EDAP Reports Record Full Year 2009 Preliminary Unaudited Results
February 16 2010 - 1:00AM
2009 Highlights:
-
Record revenue of EUR 24.9 million (USD 34.7 million),
up 7.9% year-over-year
-
Ablatherm-HIFU RPP treatments increased 24.0%
year-over-year
-
Strong EUR 12.7 million (USD 18.2 million) cash
position
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today preliminary top-line financial revenues
for the full year ended December 31, 2009. Revenue for the full
year 2009 was approximately EUR 24.9 million, an increase of 7.9%
from the full year 2008.
The Company reported record revenue growth for the third
consecutive year.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We
are pleased with our continued growth in 2009. Our top line revenue
reflected the strong sales trend achieved in our lithotripsy
business driven by our new and innovative Sonolith-Isys device.
Full year 2009 revenue also reflected ongoing market penetration
and geographic expansion of HIFU RPP activity as a preferred and
validated business model."
Mr. Oczachowski, concluded, "Delivering innovation through
our technology and business models has been our growth driver
for the past three years, and we are continuing to focus efforts on
providing non-invasive, user-friendly treatment solutions to
patients and practitioners. We are also prudently managing our
financial resources to preserve our strong cash position, as we
aggressively move forward with our long-term growth strategy."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA.
The Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment for treatment of
urinary tract stones using extra-corporeal shockwave lithotripsy
(ESWL). For more information on the company, please visit
http://www.edap-tms.com, http://www.hifu-planet.com
and http://www.pcaresearch.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. These include statements regarding the company's
growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in these forward-looking
statements. Factors that may cause such a difference include, but
are not limited to, those described in the company's filings with
the Securities and Exchange Commission. Ablatherm-HIFU treatment is
in clinical trials, but not FDA-approved or marketed in the United
States.
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
![](http://www.globenewswire.com/newsroom/ti?nf=MTYwIzE4NDI2NiM5NjIy)
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024